Takeda breaks ground on $45m Ninlaro plant in Ireland

By Staff Reporter

- Last updated on GMT

Image: iStock/dk_photos
Image: iStock/dk_photos
Takeda has begun construction of an Irish facility to support production of its orally delivered blood cancer peptide Ninlaro (ixazomib).

A groundbreaking ceremony for the €40m ($45m) facility, plans of which were first announced last December​, took place last week at Takeda’s Castle Grange biopharma site in Dublin, Ireland.

The plant will be a standalone high containment production facility dedicated to manufacturing Takeda’s multiple myeloma drug Ninlaro. It will house the drug substance, drug product, primary and secondary packaging and QC processes, and shipments of secondary packaged product are expected to begin in the second half of fiscal year 2018.

Thomas Wozniewski, head of Takeda’s Global Manufacturing & Supply said the plant is a strategic investment for the Osaka, Japan-headquartered firm.

“It will give us the crucial in-house manufacturing capacity to meet the increasing demand for our innovative product Ninlaro.”

The proteasome inhibitor works by blocking enzymes from multiple myeloma cells, hindering their ability to grow and survive, and was approved by the US Food and Drug Administration (FDA) in November 2015 for patients with multiple myeloma who have received at least one prior therapy.

It is delivered in a once-weekly pill that can be taken at home, something Takeda director Kate Burd told us late last year​ was deemed challenging to develop.

“The team faced a lot of scepticism as to whether a ‘peptide’ drug could be delivered orally. Nonetheless, our formulations and chemistry teams were able to overcome the challenges and prove it was possible.”

The peptide is currently being made in Germany and packaged in Wales.

Related news

Related products

show more

Discover Fast and Simple Water Intrusion Testing

Discover Fast and Simple Water Intrusion Testing

Pall Life Sciences | 13-Nov-2017 | Application Note

At Pall we have supported the water intrusion test for more than 20 years and we developed the Palltronic® AquaWIT IV system to deliver fast and simple...

Think all buffer filters are the same?

Think all buffer filters are the same?

Pall Life Sciences | 01-Nov-2017 | Application Note

Pall’s Supor ® buffer filters are designed for high flow rates and rapid microbial removal. This can mean dramatic reductions in buffer handling costs...

Related suppliers